This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of ...

Spontaneous tumour lysis syndrome (STLS) is a rare oncological emergency characterised by the spontaneous destruction of tumour cells in the absence of chemotherapy, with the release of large amounts ...

Because it can take some time for the cancer cells to die, tumor lysis syndrome may not happen until a few weeks after your treatment. Your doctor will monitor you for this side effect and treat ...

Among patients with heavily pretreated chronic lymphocytic leukemia, treatment with Epkinly monotherapy showed deep responses ...

The treatment for leukemia depends on many factors, including the type, subtype, and stage of the disease, and a person’s age and general health. Treatment typically involves powerful chemotherapy, ...

Although everyone’s CLL journey is different, there tend to be shared milestones that can give patients a sense of progress, ...

Researchers sought to determine whether venetoclax plus decitabine would lead to enhanced feasibility for allogeneic HSCT in patients with AML.

Kidney impairment increases the risk of tumor lysis syndrome with Venclexta. So, for these patients, we would prefer to keep them on the BTK inhibitors. Also, we wanted to avoid any combination ...

The patient was admitted to the hospital with dehydration, malnutrition, acute kidney failure, severe sepsis criteria, and with the presence of a tumor lysis syndrome. Serological investigation ...

Venetoclax was administered in the outpatient setting for 78.6% of patients, and tumor lysis syndrome (TLS) prophylaxis and venetoclax doses ranged from 70 to 400 mg, depending on concomitant ...